A Study Evaluating Toripalimab Injection Combined With Standard Chemotherapy as a First-line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Study to Evaluate the Efficacy and Safety of Toripalimab Injection (JS001) in Combination With Standard Chemotherapy Versus Placebo in Combination With Standard Chemotherapy as the 1st-line Therapy for Treatment-naive Subjects With PD-L1-positive Locally Advanced or Metastatic Urothelial Carcinoma
Sponsor: Shanghai Junshi Bioscience Co., Ltd.
This PHASE3 trial investigates Locally Advanced or Metastatic Urothelial Carcinoma and is currently ongoing. Shanghai Junshi Bioscience Co., Ltd. leads this study, which shows 5 recorded versions since 2020 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Change History
5 versions recorded-
Jan 2026 — Present [monthly]
Unknown PHASE3
Status: Not Yet Recruiting → Unknown
-
Sep 2024 — Jan 2026 [monthly]
Not Yet Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Not Yet Recruiting PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Not Yet Recruiting PHASE3
-
Oct 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Shanghai Junshi Bioscience Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Beijing, China
- • Shanghai, China